# AAML1031: sorafenib combined with chemotherapy for children with high allelic ratio FLT3-ITD acute myeloid leukaemia

Source: https://onco.cc/key-papers/paper-aaml1031-sorafenib-flt3-pollard-jco-2022/  
OnCo record `paper-aaml1031-sorafenib-flt3-pollard-jco-2022` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adding the kinase inhibitor sorafenib to chemotherapy improved event-free survival in children with high allelic ratio FLT3-ITD acute myeloid leukaemia compared with matched historical controls, the first FLT3-targeted result in paediatric leukaemia.

## Summary

Non-randomised cohort within the AAML1031 trial of 92 children with high allelic ratio FLT3-ITD AML treated with sorafenib during induction, consolidation and maintenance, compared with 76 concurrent and historical controls treated without sorafenib.

Three-year event-free survival was 55.9 versus 31.9 percent and relapse risk lower with sorafenib; benefit was concentrated in patients who received it from the first induction course, and toxicity was mostly rash and hand-foot syndrome.

## Fields

- Kind: Key paper
- Last checked: 2026-09-17
- Journal: Journal of Clinical Oncology
- Year: 2022
- DOI: 10.1200/JCO.21.01612
- Authors: Pollard JA, Alonzo TA, Gerbing R, et al.
- Findings: Three-year event-free survival 55.9 percent vs 31.9 percent.; Three-year relapse risk 22.8 percent vs 55.5 percent.
- What it means: FLT3 inhibitors are now incorporated into frontline paediatric AML therapy for FLT3-ITD, with gilteritinib being studied in the successor trial.
- Caveats: Non-randomised comparison; sorafenib patients more often had haematopoietic stem cell transplant.

## Sources

- J Clin Oncol 2022: https://doi.org/10.1200/JCO.21.01612
- PubMed: https://pubmed.ncbi.nlm.nih.gov/35349331/

## Connected records

- cancers: [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/)
- drugs: [Sorafenib](https://onco.cc/drugs/sorafenib/)
- journals: [Journal of Clinical Oncology](https://onco.cc/journals/jco/)

---
JSON: https://onco.cc/api/v1/entities/paper-aaml1031-sorafenib-flt3-pollard-jco-2022.json